阿托伐他汀对非阻塞性冠状动脉疾病患者血浆cEPCs水平及SAQ评分的影响  

Influence of atorvastatin on plasma cEPCs level and SAQ score in patients with non-obstructive coronary artery disease

作　　者：岳丹丹[1] 白艳艳[1] 刘成[1] 冯六六[1] YUE Dan-dan;BAI Yan-yan;LIU Cheng;FENG Liu-liu(Department of Cardiology,Shidong Hospital of Yangpu District of Shanghai City,Shanghai,200438,China)

机构地区：[1]上海市杨浦区市东医院心内科,上海200438

出　　处：《心血管康复医学杂志》2021年第5期535-539,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：上海市卫生和计划生育委员会科研课题(20174Y0246)。

摘　　要：目的:研究阿托伐他汀对非阻塞性冠状动脉疾病(NOCAD)患者血浆循环内皮祖细胞(cEPCs)水平及西雅图心绞痛调查表(SAQ)评分的影响。方法:我院的100例NOCAD患者被随机均分为阿托伐他汀10mg组(日接受10mg阿托伐他汀)和阿托伐他汀20mg组(日接受20mg阿托伐他汀),两组均治疗6个月。观察比较两组治疗前后血浆cEPCs水平、SAQ评分及不良反应率。结果:与治疗前比较,治疗6个月后阿托伐他汀20mg组血浆cEPCs水平[1.30(0.58,3.50)比2.40(0.68,5.03)]、SAQ躯体活动受限程度评分[(25.70±6.25)分比(26.75±6.17)分]、心绞痛稳定状态评分[(3.28±0.67)分比(3.52±0.53)分]、治疗满意程度评分[(13.47±1.33)分比(14.18±1.73)分]及SAQ总分[(56.52±6.21)分比(58.94±6.32)分]均显著升高(P<0.05或<0.01)。与阿托伐他汀10mg组比较,治疗6个月后阿托伐他汀20mg组SAQ心绞痛稳定状态评分[(3.23±0.71)分比(3.52±0.53)分]显著升高,P=0.025。两组不良反应率无显著差异(P均>0.05)。结论:日20mg阿托伐他汀能显著升高NOCAD患者血浆cEPCs水平,并缓解心绞痛症状,提高治疗满意度。Objective:To study influence of atorvastatin on plasma level of circulating endothelial progenitor cells(cEPCs)and Seattle angina questionnaire(SAQ)score in patients with non-obstructive coronary artery disease(NOCAD).Methods:A total of 100 NOCAD patients were divided into atorvastatin 10mg group(received atorvastatin 10mg/d)and atorvastatin 20mg group(received atorvastatin 20mg/d),both groups were treated for 6 months.Plasma cEPCs level,SAQ score before and after treatment and incidence rate of adverse reactions were observed and compared between two groups.Results:Compared with before treatment,after 6-month treatment,there were significant rise in plasma cEPCs level[1.30(0.58,3.50)vs.2.40(0.68,5.03)],scores of SAQ physical limitation[(25.75±5.61)scores vs.(26.75±6.17)scores],anginal stability[(3.23±0.71)scores vs.(3.52±0.53)scores]and treatment satisfaction[(13.77±1.35)scores vs.(14.18±1.73)scores]and SAQ total score[(57.09±6.17)scores vs.(58.94±6.32)scores]in atorvastatin 20mg group(P<0.05 or<0.01).Compared with atorvastatin 10mg group,after 6-month treatment,there was significant rise in score of SAQ anginal stability[(3.23±0.71)scores vs.(3.52±0.53)scores]in atorvastatin 20mg group,P=0.025.There was no significant difference in incidence rate of adverse reactions between two groups(P<0.05 all).Conclusion:20mg/d atorvastatin treatment can increase plasma cEPCs level,relieve symptoms of angina pectoris and improve treatment satisfaction in NOCAD patients.

关 键 词：冠状动脉疾病 心绞痛 干细胞 

分 类 号：R541.4[医药卫生—心血管疾病]